EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Temozolomide‐Promoted MGMT Transcription Contributes to Chemoresistance by Activating the ERK Signalling Pathway in Malignant Melanoma

Meiyi Deng, Bingjie Ren, Jing Zhao, Xia Guo, Yuanyuan Yang, Huiling Shi, Xuyu Bian, Mengyao Wu, Caihua Xu, Min Tao, Rongrui Liang iD, Qiang Li iD

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Meiyi Deng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Temozolomide, Melanoma, Drug Resistance, Neoplasm, DNA Repair Enzymes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gusu Health Talent Program, The Open Fund for Scientific Research of Jiangxi Cancer Hospital, Jiangsu Government Scholarship for Oversea Studies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumour cells possess a multitude of chemoresistance mechanisms, which could plausibly contribute to the ineffectiveness of chemotherapy. O 6 ‐methylguanine‐DNA methyltransferase (MGMT) is an important effector protein associated with Temozolomide (TMZ) resistance in various tumours. To some extent, the expression level of MGMT determines the sensitivity of cells to TMZ, but the mechanism of its expression regulation has not been fully elucidated. Cultured malignant melanoma cell lines A375 and Sk‐MEL28 were employed. A luciferase assay was used to detect the transcriptional activity of the MGMT promoter. Western blotting was used to compare the expression levels of phosphorylated ERK1/2 (P‐ERK1/2) after TMZ treatment. Immunofluorescent staining was used to detect TMZ‐induced DNA damage protein levels. The sensitivity of melanoma cells to TMZ was detected by MTT assay and animal experiments. The expression of MGMT mRNA was tested by Quantitative real‐time PCR (RT‐qPCR). Flow cytometry was used to measure the apoptosis of TMZ‐treated cells. TMZ enhanced the transcription of MGMT through activating the ERK pathway. ERK inhibitors U0126 and vemurafenib (vMF) inhibited the TMZ induced transcription of MGMT. The expression of MGMT and p‐ERK1/2 was closely related in human MM tissues. vMF increased the sensitivity of melanoma (MM) to TMZ in vitro and in vivo through downregulating MGMT and promoting the TMZ induced DNA damage in MM. TMZ‐promoted MGMT transcription contributed to instinctive chemoresistance by activating the ERK signalling pathway in malignant melanoma. Our study indicates that the use of the ERK inhibitor in combination with TMZ could potentially enhance the effectiveness of clinical treatment for malignant melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideMelanomaDrug Resistance, NeoplasmDNA Repair EnzymesMAP Kinase Signaling SystemTumor Suppressor ProteinsDNA Modification MethylasesTranscription, GeneticHumansCell Line, TumorGene Expression Regulation, NeoplasticAnimalsApoptosisMice, NudeAntineoplastic Agents, AlkylatingMicePromoter Regions, GeneticVemurafenibXenograft Model Antitumor AssaysDNA Damage

Stichwörter der Autor:innen

MAPK/ERK pathwayMGMTchemoresistancemelanomatemozolomide

Substanzen

TemozolomideDNA Repair EnzymesTumor Suppressor ProteinsMGMT protein, humanDNA Modification MethylasesAntineoplastic Agents, AlkylatingVemurafenib

Autor:innen und Institutionen

  • Department of Oncology, The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Division of Clinical Oncology, Medical Center of Soochow University, Suzhou, Jiangsu, China.
  • Suzhou Sano Precision Medicine Ltd, Suzhou, Jiangsu, China.
  • Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Department of Oncology, Nanyang Second General Hospital, Nanyang, Henan, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

ORCID-Profile: Rongrui Liang, Qiang Li

Förderung

  • Gusu Health Talent Program
  • The Open Fund for Scientific Research of Jiangxi Cancer Hospital
  • Jiangsu Government Scholarship for Oversea Studies
  • Suzhou Science and Technology Plan
  • Clinical Research Project of Wu Jieping Medical Foundation
  • the National Natural Science Foundation of China
  • Clinical Medicine peak project of Soochow Medical College, Soochow University
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Deng, M., Ren, B., Zhao, J., Guo, X., Yang, Y., Shi, H., Bian, X., Wu, M., Xu, C., Tao, M., Liang, R., & Li, Q. (2025). Temozolomide‐Promoted MGMT Transcription Contributes to Chemoresistance by Activating the ERK Signalling Pathway in Malignant Melanoma. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70380

Vancouver

Deng M, Ren B, Zhao J, Guo X, Yang Y, Shi H, et al. Temozolomide‐Promoted MGMT Transcription Contributes to Chemoresistance by Activating the ERK Signalling Pathway in Malignant Melanoma. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70380

BibTeX
@article{Deng2025,
  author = {Deng, Meiyi and Ren, Bingjie and Zhao, Jing and Guo, Xia and Yang, Yuanyuan and Shi, Huiling and Bian, Xuyu and Wu, Mengyao and Xu, Caihua and Tao, Min and Liang, Rongrui and Li, Qiang},
  title = {Temozolomide‐Promoted MGMT Transcription Contributes to Chemoresistance by Activating the ERK Signalling Pathway in Malignant Melanoma},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70380}
}
Kostenlos starten →